TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29166336
Drug: Preemptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive treatment (2 × 900 mg/d initiated at viral load of 400 CMV copies/mL or greater)
Study: 29166336
Drug: Preemptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive treatment
Study: 23796315
Drug: Exposure group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure group therapy
Study: 25199046
Drug: Pre-treatment symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment symptom severity, race, age, gender
Study: 23253305
Drug: Third wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third wave cognitive therapy
Study: 23253305
Drug: Mentalization-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based therapy
Study: 17507365
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both predictors (APC/h and max HR)
Study: 12189364
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac tromethamine (intravenous)
Study: 12189364
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ketorolac tromethamine (intramuscular or submucosal)
Study: 12189364
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ketorolac tromethamine (at the surgical site)
Study: 2197908
Drug: Fluconazole, 400
Normalized name: Fluconazole, 400 mg/200 mL-5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole, 400 mg/d for 10 weeks
Study: 282084
Drug: Three distinct
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three distinct antihypertensive drugs, administered alone and combined two‐by‐two.
Study: 31791209
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: voltage, 100 kVp, iodixanol, 270 mgI/mL
Study: 31791209
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: voltage, 120 kVp; iohexol, 350 mgI/mL
Study: 25973914
Drug: Bacillus clausii
Normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus clausii spores administered as lyophilized or liquid formulation
Study: 25973914
Drug: Bacillus clausii
Normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus clausii spores (liquid suspension)
Study: 23332366
Drug: Nebivolol (NEB)
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol (NEB) 5 mg/d, titrated to 20 mg/d
Study: 21889878
Drug: Lurasidone 120
Normalized name: lurasidone 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 120 mg once daily
Study: 23277250
Drug: Ziprasidone 80
Normalized name: ziprasidone 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 80 mg BID
Study: 19498438
Drug: Efonidipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efonidipine (40 mg day(-1))
Study: 19498438
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg day(-1))
Study: 16979844
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose 30 Gy (dose/fraction 1.5 Gy, 16 patients)
Study: 16979844
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose 25.5 Gy (dose/fraction 1.5 Gy, 62 patients)
Study: 16979844
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose 20 Gy (dose/fraction 2 Gy, 69 patients)
Study: 16979844
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose 26 Gy (dose/fraction 2 Gy, 29 patients)
Study: 15003662
Drug: Autoclaved‐killed, whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoclaved‐killed, whole cell Leishmania amazonensis vaccine plus BCG adjuvant
Study: 1775603
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor HP 029 (doses not specified)
Study: 29351310
Drug: Small-group intervention
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-group intervention of seven weekly sessions of 120 min with a booster session after six weeks
Study: 22159880
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (1.0 mL/kg of bupivacaine 0.166% with epinephrine 1:600,000)
Study: 22159880
Drug: Group BM
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group BM (1.0 mL/kg of bupivacaine 0.166% with epinephrine 1:600,000 plus morphine 20 μg/kg)
Study: 22159880
Drug: Group BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group BC (bupivacaine 0.166% with epinephrine 1:600,000 plus clonidine 1.0 μg/kg)
Study: 22159880
Drug: Group BMC
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group BMC (bupivacaine 0.166% with epinephrine 1:600,000 plus morphine 20 μg/kg and clonidine 1.0 μg/kg)
Study: 19889003
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy with added pioglitazone (45 mg)
Study: 15762971
Drug: Single-dose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefazolin (1 g intravenously before surgery)
Study: 15762971
Drug: 1-day cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-day cefazolin (1 g intravenously before surgery and three more doses every 6 hr after surgery)
Study: 11879210
Drug: Propofol-ephedrine combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-ephedrine combination
Study: 7604787
Drug: Fluvastatin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin at 40 mg/day
Study: 2196555
Drug: Codeine plus
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine plus 1 g of paracetamol t.i.d.
Study: 2196555
Drug: Paracetamol t.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol t.i.d.
Study: 27093610
Drug: GSK457 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK457 (40 g/day)
Study: 17450046
Drug: Risperidone (1.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1.08 mg/day)
Study: 9690573
Drug: Salmeterol powder
Normalized name: salmeterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol powder (50 microg twice daily)
Study: 31778140
Drug: Ens-Grad machine
Normalized name: GRAd-COV2
DrugBank: GRAd-COV2 (DB16428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ens-Grad machine learning method for designing complementarity determining regions of human Immunoglobulin G antibodies
Study: 26233289
Drug: N-palmitoylethanolamine (PEA)
Normalized name: N-palmitoylethanolamine
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-palmitoylethanolamine (PEA) and transpolydatin: 400 mg + 40 mg (1 tablet a day for 10 days from the 24th day of cycle)
Study: 26233289
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet a day for 10 days from the 24th day of cycle)
Study: 18719439
Drug: Dexmedetomidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.3 and 0.6 ng/ml)
Study: 18719439
Drug: Dexmedetomidine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (up to 0.6 ng/ml)
Study: 15772567
Drug: Soy supplements
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplements (Novasoy, 60 mg total isoflavone equivalents/day)
Study: 10980842
Drug: Intravenous IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous IIb/IIIa blockade
Study: 6253303
Drug: Hormones and
Normalized name: HORMONES AND RELATED AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormones and hormones and thiazide
Study: 30183583
Drug: TACE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE therapy
Study: 16310262
Drug: Standard HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HF therapy
Study: 26301344
Drug: Overall HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall HF therapy
Study: 23653910
Drug: Paediatric fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paediatric fixed-dose combination granule for reconstitution (lamivudine/zidovudine/nevirapine 30/60/50 mg per 5 ml)
Study: 11008919
Drug: CagA protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CagA protein antibodies
Study: 8341859
Drug: Fenoterol/Ipratropium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol/Ipratropium Bromide (F/IB; 0.1 mg/0.04 mg)
Study: 8341859
Drug: Salbutamol (S;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (S; 0.2 mg)
Study: 3786603
Drug: Intravenous GABA
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GABA administration
Study: 19713950
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR therapy (placebo-controlled trial)
Study: 18652113
Drug: Allopurinol tablet
Normalized name: Allopurinol Tablets
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol tablet
Study: 15975300
Drug: Xuesaitong soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong soft capsule (XST)
Study: 15975300
Drug: Dahuang Zhechong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dahuang Zhechong pill (NFDA1)
Study: 14769157
Drug: Training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training program for health personnel including social, cultural, and economic aspects of tuberculosis, diagnosis and treatment, and establishment of self-help groups. Patients received a short-term treatment regimen with isoniazid, rifampin, pyrazinamide, and ethambutol for 25 weeks (105 doses).
Study: 14769157
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received standard treatment without the educational intervention.
Study: 1406078
Drug: Recombinant alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha‐2b interferon treatment 3 MU three times weekly for 36 weeks
Study: 27846344
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg monthly for 76 weeks)
Study: 22840762
Drug: Transcranial magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial magnetic stimulation (TMS) treatment to the left temporoparietal cortex for 10 days
Study: 20820916
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg twice daily
Study: 18549466
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (TG)
Study: 18549466
Drug: Dihydrotestosterone gel
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone gel (DHTG)
Study: 17299466
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose vitamin A (5000 IU per day)
Study: 17299466
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose vitamin A (200,000 IU)
Study: 11292011
Drug: Ayahuasca (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (0.5 mg DMT/kg body weight)
Study: 11292011
Drug: Ayahuasca (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (0.75 mg DMT/kg body weight)
Study: 11292011
Drug: Ayahuasca (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (all doses)
Study: 11292011
Drug: Ayahuasca (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (medium dose)
Study: 9331003
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (8, 12, or 16 mg)
Study: 3221745
Drug: (R)-propafenone 250
Normalized name: (+)-(r)-propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-propafenone 250 mg
Study: 3221745
Drug: (S)-propafenone 250
Normalized name: (-)-(S)-Propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-propafenone 250 mg
Study: 30001760
Drug: Step 15
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 15 exposure therapy (allowing a spider to walk freely over one's body)
Study: 30001760
Drug: Step 14
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Step 14 or fewer exposure therapy steps
Study: 25720854
Drug: ASR implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASR implants
Study: 25720854
Drug: ReCap implants
Normalized name: recAP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReCap implants
Study: 22147343
Drug: Chinese preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese preparation of rhGH (GenHeal®, 1.6 mg (4 IU), Shanghai, China) administered at a dose of 0.1 IU/kg body weight, one injection per day for 14 days.
Study: 22147343
Drug: Swiss preparation
Normalized name: Swiss Kriss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swiss preparation of rhGH (Saizen®, 1.33 mg (4 IU), Laboratoires Serone S.A., Switzerland) administered at a dose of 0.1 IU/kg body weight, one injection per day for 14 days.
Study: 18972290
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate (BDP; 400 microg/d)
Study: 15614573
Drug: 0.42 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42 mg/kg dexamphetamine
Study: 22030902
Drug: Dual cholate
Normalized name: cholate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual cholate (CA) clearance after oral administration (Cl(oral))
Study: 22030902
Drug: CA Cl(oral)
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA Cl(oral) or PHM
Study: 15983093
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose (5 g in 50 ml)
Study: 15983093
Drug: 50% dextrose
Normalized name: DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 50% Dextrose]
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% dextrose (5 g in 10 ml)
Study: 16843455
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg twice daily)
Study: 8520499
Drug: Myeloablative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloablative therapy supported by autologous bone marrow or blood stem cell transplantation
Study: 1836486
Drug: Accelerated vaccination
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated vaccination schedule with recombinant hepatitis B vaccine (Engerix-B)
Study: 6769666
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (500 mg) in fasting (A)
Study: 6769666
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (500 mg) with a meal (B)
Study: 6769666
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (500 mg) 3 hours after a meal (C)
Study: 6769666
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus dose of VPA (400 mg) 3 hours after a meal
Study: 27574418
Drug: Self-management program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management program (group education session, individual training on inhalation techniques, written action plan)
Study: 17295569
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment negative ratings
Study: 17295569
Drug: Positive ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive ratings in the 1st half of treatment
Study: 16232343
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of Bacillus Calmette‐Guérin polysaccharide nucleotide (BCG‐PSN)
Study: 16232343
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of BCG‐PSN
Study: 16232343
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of BCG‐PSN (36 times)
Study: 11793634
Drug: Celecoxib as
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib as adjunctive therapy
Study: 10783843
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Ultra Plaque Remover (D9)
Study: 11350520
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B 3D Plaque Remover (3D)
Study: 2727071
Drug: Developmental physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developmental physical therapy program (six one-minute activities in side-lying and supported-sitting positions)
Study: 2727071
Drug: Developmental physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developmental physical therapy program
Study: 799561
Drug: Metoprolol (75-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (75-300 mg)
Study: 31483155
Drug: Acute antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute antioxidant (AO) administration (600 mg α-lipoic acid, 1,000 mg vitamin C, and 600 IU vitamin E)
Study: 31483155
Drug: Acute antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute antioxidant (AO) administration
Study: 16461147
Drug: Peanut flour
Normalized name: Peanut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut flour (doses ranging from 10 microg to 3 g)
Study: 16461147
Drug: Peanut flour
Normalized name: Peanut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut flour (doses ranging from 10 mg to 3 g)
Study: 15238773
Drug: Oral ALCAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ALCAR (1500 mg twice daily) for up to 33 months
Study: 9300221
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human insulin-like growth factor-1 (rhIGF-I)
Study: 3534801
Drug: 112.5 mg
Normalized name: lotilaner 112.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 112.5 mg hydrochlorothiazide
Study: 22709745
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy on the background of early revascularization (either percutaneous coronary intervention or coronary artery bypass grafting)
Study: 21164555
Drug: Flavored water
Normalized name: FLAVOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored water with 6% carbohydrate and 18 mmol·L‐1 NaCl (CNa)
Study: 12799509
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal conjugate vaccine (PnCRM9)
Study: 12799509
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (meningococcus C vaccine)
Study: 10423078
Drug: Newer classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer classes of blood pressure lowering drugs
Study: 2580164
Drug: Captopril and
Normalized name: captopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril and Enalapril (combined therapy)
Study: 2580164
Drug: Captopril and
Normalized name: captopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril and Enalapril (after prolonged treatment)
Study: 30017552
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (75–100 mg)
Study: 30017552
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of aspirin (≥325 mg)
Study: 24201303
Drug: Conventional programming
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional programming with therapy for ventricular tachycardia ≥170 bpm
Study: 24201303
Drug: High-rate cutoff
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-rate cutoff with therapy for ventricular tachycardia ≥200 bpm and a monitoring zone at 170 to 199 bpm
Study: 24201303
Drug: Prolonged 60-second
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged 60-second delay with a monitoring zone before therapy
Study: 23128163
Drug: AMG145 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 280 mg
Study: 23128163
Drug: AMG145 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 350 mg
Study: 23128163
Drug: AMG145 420
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 420 mg
Study: 23128163
Drug: AMG145 420
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 420 mg + Ezetimibe 10 mg
Study: 23128163
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Ezetimibe 10 mg
Study: 21410069
Drug: Menatetrenone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (4 5mg daily, orally)
Study: 17961145
Drug: Oral 17‐beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17‐beta estradiol
Study: 17961145
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and vaginal 17‐beta estradiol
Study: 16632842
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anesthesia (CSA) with titration of 2.5 mg boluses every 15 min of isobaric bupivacaine
Study: 16632842
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection spinal anesthesia (SA) with 7.5 mg of isobaric bupivacaine
Study: 11267624
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral hydrocortisone